Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vertex Pharmaceuticals (VRTX) closed at $492.47 in the latest trading session, marking a +0.01% move from the prior day.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The CHMP recommended granting a marketing authorization for Alyftrek, a medicine intended for the treatment of cystic fibrosis in people aged ...

VERTEX PHARMACEUTICALS INC (VRTX) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the ...

Vertex Pharmaceuticals Inc. closed 5.66% below its 52-week high of $519.88, which the company reached on November 8th.

Read Our Latest Report on Vertex Pharmaceuticals Vertex Pharmaceuticals Trading Up 2.4 % Shares of VRTX stock opened at $495.83 on Monday. Vertex Pharmaceuticals has a fifty-two week low of $377. ...

VERTEX PHARMACEUTICALS INC (VRTX) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $512.41. A number of research firms have recently commented on VRTX. Canaccord ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.37% to $477.52 Monday, on what proved to be an all-around dismal trading ...